Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions

British Journal of Radiology

Volumn 84, Issue 1002, 2011, Pages 526-533

  Hainfeld, James F ^a   O'Connor, M J ^a   Dilmanian, F A ^b,c   Slatkin, D N ^a   Adams, D J ^d   Smilowitz, H M ^d  

^a Nanoprobes Incorporated   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GOLD NANOPARTICLE; MACROGOL; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BREAST CANCER; CANCER CELL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; DRUG CARRIERS; FEMALE; GOLD; MICE; MICE, NUDE; NANOPARTICLES; X-RAY MICROTOMOGRAPHY;

EID: 79956348496     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/42612922     Document Type: Article

References (47)

1. Popovtzer R, Agrawal A, Kotov NA, Popovtzer A, Balter J, Carey TE, et al. Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett 2008;8:4593-6.
2. Cai QY, Kim SH, Choi KS, Kim SY, Byun SJ, Kim KW, et al. Colloidal gold nanoparticles as a blood-pool contrast agent for X-ray computed tomography in mice. Invest Radiol 2007;42:797-806. (Pubitemid 350126561)
3. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol 2006;79:248-53.
4. Gobin AM, Lee MH, Halas NJ, James WD, Drezek RA, West JL. Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett 2007;7:1929-34. (Pubitemid 47197569)
5. Qian X, Peng XH, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol 2008;26:83-90.
6. Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004;11:169-83.
7. von Maltzahn G, Park JH, Agrawal A, Bandaru NK, Das SK, Sailor MJ, et al. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res 2009;69:3892-900.
8. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 2004;49:N309-15.
9. Cho SH. Estimation of tumour dose enhancement due to gold nanoparticles during typical radiation treatments: a preliminary Monte Carlo study. Phys Med Biol 2005;50:N163-73.
10. Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancementwith gold nanoparticles. J Pharm Pharmacol 2008;60:977-85.
11. McMahon SJ, Mendenhall MH, Jain S, Currell F. Radiotherapy in the presence of contrast agents: a general figure of merit and its application to gold nanoparticles. Phys Med Biol 2008;53:5635-51.
12. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38. (Pubitemid 24194147)
13. Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nature Phys Res 1973;241:20-2.
14. Takae S, Akiyama Y, Otsuka H, Nakamura T, Nagasaki Y, Kataoka K. Ligand density effect on biorecognition by PEGylated gold nanoparticles: regulated interaction of RCA120 lectin with lactose installed to the distal end of tethered PEG strands on gold surface. Biomacromolecules 2005;6:818-24. (Pubitemid 40476053)
15. Cuatrecasas P, Parikh I. Adsorbents for affinity chromatography. Use of N-hydroxysuccinimide esters of agarose. Biochemistry 1972;11:2291-9.
16. Wise PM, Camp-Grossman P, Barraclough CA. Effects of estradiol and progesterone on plasma gonadotropins, prolactin, and LHRH in specific brain areas of ovariectomized rats. Biol Reprod 1981;24:820-30. (Pubitemid 11043210)
17. Dubal DB, Wise PM. Neuroprotective effects of estradiol in middle-aged female rats. Endocrinology 2001;142:43-8. (Pubitemid 32183664)
18. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localisation but does increase internalisation in animal models. Cancer Res 2006;66:6732-40. (Pubitemid 44085631)
19. Hubbell JH, Seltzer SM. Tables of X-ray mass attenuation coefficients and mass energy-absorption coefficients. 1996. Accessed 3 May 2009. Available from: http://physics.nist.gov/PhysRefData/XrayMassCoef/tab4.html.
20. Andrew SM, Johnstone RW, Russell SM, McKenzie IF, Pietersz GA. Comparison of in vitro cell binding characteristics of four monoclonal antibodies and their individual tumor localisation properties in mice. Cancer Res 1990;50:4423-8. (Pubitemid 20225689)
21. Grunberg J, Novak-Hofer I, Honer M, Zimmermann K, Knogler K, Blauenstein P, et al. In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin Cancer Res 2005;11:5112-20.
22. Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005;32:51-8.
23. Haigler HT, McKanna JA, Cohen S. Direct visualisation of the binding and internalisation of a ferritin conjugate of epidermal growth factor in human carcinoma cells A-431. J Cell Biol 1979;81:382-95. (Pubitemid 9162943)
24. Wuang SC, Neoh KG, Kang ET, Pack DW, Leckband DE. HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetisation. Biomaterials 2008;29:2270-9.
25. Chong HS, Song HA, Ma X, Milenic DE, Brady ED, Lim S, et al. Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI. Bioconjug Chem 2008;19:1439-47. (Pubitemid 352032344)
26. Zhu W, Okollie B, Bhujwalla ZM, Artemov D. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med 2008;59:679-85. (Pubitemid 351501930)
27. Cheng Z, De Jesus OP, Namavari M, De A, Levi J, Webster JM, et al. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 2008;49:804-13.
28. Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res 2008;14:3840-9.
29. Takeda M, Tada H, Higuchi H, Kobayashi Y, Kobayashi M, Sakurai Y, et al. In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine. Breast Cancer 2008;15:145-52.
30. Koyama Y, Barrett T, Hama Y, Ravizzini G, Choyke PL, Kobayashi H. In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 2007;9:1021-9.
31. Bhattacharyya S, Wang S, Reinecke D, Kiser W, Jr., Kruger RA, DeGrado TR. Synthesis and evaluation of near-infrared (NIR) dye-herceptin conjugates as photoacoustic computed tomography (PCT) probes for HER2 expression in breast cancer. Bioconjug Chem 2008;19:1186-93. (Pubitemid 351874940)
32. Welsher K, Liu Z, Daranciang D, Dai H. Selective probing and imaging of cells with single walled carbon nanotubes as near-infrared fluorescent molecules. Nano Lett 2008;8:586-90. (Pubitemid 351346022)
33. Hillyer JF, Albrecht RM. Correlative instrumental neutron activation analysis, light microscopy, transmission electron microscopy, and X-ray microanalysis for qualitative and quantitative detection of colloidal gold spheres in biological specimens. Microsc Microanal 1998;4:481-90.
34. Hillyer JF, Albrecht RM. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J Pharm Sci 2001;90:1927-36. (Pubitemid 33144438)
35. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release 2006;114:343-7. (Pubitemid 44310822)
36. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 2008;66:274-80.
37. Terentyuk GS, Maslyakova GN, Suleymanova LV, Khlebtsov BN, Kogan BY, Akchurin GG, et al. Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery. J Biophotonics 2009;2:292-302.
38. Zhang G, Yang Z, Lu W, Zhang R, Huang Q, Tian M, et al. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials 2009;30:1928-36.
39. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998;89:307-14. (Pubitemid 28197296)
40. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterisation of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95-109.
41. Paulus MJ, Gleason SS, Kennel SJ, Hunsicker PR, Johnson DK. High resolution X-ray computed tomography: an emerging tool for small animal cancer research. Neoplasia 2000;2:62-70. (Pubitemid 30123181)
42. Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005;11:4810-17. (Pubitemid 41568167)
43. Storto G, Buchegger F, Waibel R, Kuenzi G, Offord RE, Schubiger PA, et al. Biokinetics of a F(ab′)3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma. Cancer Biother Radiopharm 2001;16:371-9. (Pubitemid 33151114)
44. Beatty JD, Duda RB, Williams LE, Sheibani K, Paxton RJ, Beatty BG, et al. Preoperative imaging of colorectal carcinoma with 111In-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res 1986;46:6494-502. (Pubitemid 17221807)
45. Takahashi N, Hartman RP, Vrtiska TJ, Kawashima A, Primak AN, Dzyubak OP, et al. Dual-energy CT iodine-subtraction virtual unenhanced technique to detect urinary stones in an iodine-filled collecting system: a phantom study. AJR Am J Roentgenol 2008;190:1169-73. (Pubitemid 351684915)
46. Wang ZJ, Coakley FV, Fu Y, Joe BN, Prevrhal S, Landeras LA, et al. Renal cyst pseudoenhancement at multidetector CT: what are the effects of number of detectors and peak tube voltage? Radiology 2008;248:910-16.
47. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007;9:257-88. (Pubitemid 350246658)